HALO Halozyme Therapeutics, Inc.
HALO Halozyme Therapeutics, Inc.
Healthcare · Biotechnology
Market read
Scan convergence 1 scan as of 2026-10-16 1 bull converging
POC $70.16 · VWAP $79.43 · +53.4% vs 12m avg buyer
Insiders quiet 0 buy / 0 sell · Form 4, 90d
Cluster CEO, Director sold $7.2M, Oct 2–8
Coverage
1 watchlist
HALO Price Structure
Loading timeframes…
Peers
Every watchlist HALO belongs to, members best 30-day change first — HALO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@monster-discoveries
Reported EPS $2.28 versus analyst consensus of $1.82 (+25.5%).
full note →Against street estimates
How HALO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
HALO research tape
71 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.